Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first ...
The Manila Times

Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies

Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas ...
ascopubs.org

A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors.

Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy ...